Singapore vs Togo: Access to anti-retroviral drugs, male
Singapore
86.0%
in 2023
Togo
86.0%
in 2024
Singapore rank
30th
Togo rank
30th
Access to anti-retroviral drugs, male over time
- Singapore
- Togo
How they compare
Singapore currently reports 86.0% against 86.0% in Togo, a difference of 0.0%.
Across all 24 years both countries report, Singapore has been ahead every year.
Singapore ranks 30th and Togo ranks 30th of 141 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Singapore | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 18.5% | 6.1% | 12.4% | Singapore |
| 2010s | 71.2% | 37.6% | 33.6% | Singapore |
| 2020s | 85.2% | 71.2% | 14.0% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Singapore or Togo?
- Singapore, at 86.0% against 86.0% in Togo as of 2023.
- What is the difference in access to anti-retroviral drugs, male between Singapore and Togo?
- 0.0%, with Singapore ahead.
- How many years of comparable data are there for Singapore and Togo?
- 24 years are reported by both, from 2000 to 2023.
- How do Singapore and Togo rank globally for access to anti-retroviral drugs, male?
- Singapore ranks 30th and Togo ranks 30th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.